Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-label, Multicenter Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia (AML) and Treatment-naïve Subjects With AML Who Are Not Eligible for Intensive Induction Chemotherapy
Conditions
Interventions
CC-90011
Venetoclax
+3 more
Locations
17
United States
Local Institution - 110
Duarte, California, United States
Local Institution - 103
New Haven, Connecticut, United States
Local Institution - 108
Miami, Florida, United States
Local Institution - 111
Chicago, Illinois, United States
Local Institution - 121
New York, New York, United States
Local Institution - 118
Durham, North Carolina, United States
Start Date
October 14, 2021
Primary Completion Date
March 9, 2022
Completion Date
March 9, 2022
Last Updated
March 2, 2023
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06537726
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions